



# Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25

2021-02-04

*Conference Call and Webcast Scheduled for 1:30 p.m. PST*

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2020 financial results after the market close on Thursday, February 25, 2021. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 25, 2021.

A link to the live webcast will be available on the company's website at <http://investors.glaukos.com>. To participate in the conference call, please dial 833-231-8262 (U.S.) or 647-689-4107 (International) and enter Conference ID 4167849. A replay will be archived on the company's website following completion of the call.

## **About Glaukos**

Glaukos ([www.glaukos.com](http://www.glaukos.com)) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the *iStent*<sup>®</sup>, its first MIGS device, in the United States in July 2012, its next-generation *iStent inject*<sup>®</sup> device in the United States in September 2018, and most recently, the *iStent inject W* device in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version  
on [businesswire.com](https://www.businesswire.com/news/home/20210204005172/en/): <https://www.businesswire.com/news/home/20210204005172/en/>

Chris Lewis  
Director, Investor Relations, Corporate Strategy & Development  
(949) 481-0510  
[clewis@glaukos.com](mailto:clewis@glaukos.com)

Source: Glaukos Corporation